Author  
Place of duty  
Title   침윤성 흉선종에 대한 Cyclophosphamide , Adriamycin , Cisplatin ( CAP ) 복합화학요법 ( Cyclophosphamide , Adriamycin and Cisplatin ( CAP ) Combination Chemotherapy for Invasive Thymoma )
Publicationinfo   1990 Jan; 022(03): 532-539.
Key_word  
Full-Text  
Abstract   Between October 1985 and January 1990, the combination chemotherapy with cyclophosphamide, adriamycin and cisplatin (CAP) has been administered in 16 patients with invasive, recurrent or metastatic thymoma. Among 14 evaluable patients, 1 patient(7%) achieved a complete response and 4 patients (29%) had a partial response. The 4 year overall survival rates were 56.7% with a median follow-up of 11.5 months. The mast frequent hematologic toxicity was leukopenia (15.9%) and nonhematologic toxicity (WHO criteria; grade II) were alopecia (80%) and nausea/vomiting (66.7%). The CAP regimen is effective and well tolerated for the treatment of invasive thymoma, and further study is needed to confirm the relative effectiveness of CAP regimen in comparison with other regimens and to find out the prognostic factors related to response rate and survival
저 자   박영석(Young Suk Park),임영혁(Young Hyuk Im),강원기(Won Ki Kang),서창인(Chang In Suh),이기형(Kee Hyung Lee),정경해(Kyung Hae Jung),김흥태(Heung Tae Kim),허대석(Dae Seog Heo),방영주(Yung Jue Bang),김노경(Noe Kyeong Kim)